drugset / Trial / NCT01928628

Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients

NCT01928628

Phase 3 Completed 449 enrolled LG Life Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims to compare and assess the efficacy and the safety of the combination agent of Lercanidipine and Valsartan and monotherapy of Lercanidipine alone in patients with essential hypertension

Timeline

Start
2012-05
Primary completion
2013-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lercanidipine Small molecule 10 mg
Subject Valsartan Small molecule 80 mg
Subject Valsartan Small molecule 160 mg